Mechanisms supporting Psilocybin-Assisted Psychotherapy for Alcohol Use Disorder: A randomized, controlled clinical trial


The aim of this study is to determine if a single dose of psilocybin administered with motivational enhancement therapy (MET) can reduce heavy drinking in patients with an alcohol use disorder (AUD).

Eligible participants will be randomly allocated into either a high or low psilocybin dose group. All participant will be paired with a therapist and will receive up to 8 hours of preparation work prior to dosing. Following dosing participants will receive 5 weekly therapy sessions.

Clinical, behavioral and neuroimaging measures will be completed at various time points throughout the study.


Currently recruiting participants: Yes

Eligible gender: Male, Female, Transgender, Other

Eligible ages: 22 to 65

Inclusion criteria:

- Aged 22-65
- Regularly consume alcohol and wish to decrease consumption
- Limited lifetime hallucinogen use

Exclusion criteria:

- Diagnosis of; schizophrenia, bipolar disorders, or active suicidal ideation
- Currently pregnant, nursing, or trying to become pregnant


Fill out the following form if you want to participate in this research

Method of contact

Additional information

Contact information

If you are interested in applying for this study please complete the preliminary-screening form here: OR contact if you have any questions.

Principal investigator:

Valerie Taylor

Clinical trial: